Compare GAME & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAME | BCTX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | Canada |
| Employees | N/A | 4 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 36.6M |
| IPO Year | 2024 | 2025 |
| Metric | GAME | BCTX |
|---|---|---|
| Price | $3.06 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 174.3K | ★ 186.3K |
| Earning Date | 04-08-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,999,302.00 | N/A |
| Revenue This Year | $87.12 | N/A |
| Revenue Next Year | $21.14 | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $2.60 |
| 52 Week High | $3.85 | $14.68 |
| Indicator | GAME | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
GameSquare Holdings Inc is a vertically integrated digital media, entertainment, and technology company focused on gaming and youth culture audiences. The company operates through four reportable segments: Owned and Operated IP, Agency, SaaS and managed services, and Yield. It provides services including influencer marketing, esports talent management, creative production, merchandise and consumer products, live streaming analytics, and digital media solutions through its various brands and platforms. It generates the majority of its revenue from the Agency segment.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.